AU2020298316A1 - Exosomes for disease treatment - Google Patents
Exosomes for disease treatment Download PDFInfo
- Publication number
- AU2020298316A1 AU2020298316A1 AU2020298316A AU2020298316A AU2020298316A1 AU 2020298316 A1 AU2020298316 A1 AU 2020298316A1 AU 2020298316 A AU2020298316 A AU 2020298316A AU 2020298316 A AU2020298316 A AU 2020298316A AU 2020298316 A1 AU2020298316 A1 AU 2020298316A1
- Authority
- AU
- Australia
- Prior art keywords
- exosomes
- disease
- condition
- disorder
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 391
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 154
- 201000010099 disease Diseases 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 124
- 208000035475 disorder Diseases 0.000 claims abstract description 89
- -1 CD11c Proteins 0.000 claims abstract description 73
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 102100025222 CD63 antigen Human genes 0.000 claims abstract description 32
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims abstract description 32
- 102100037904 CD9 antigen Human genes 0.000 claims abstract description 31
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims abstract description 31
- 102100027221 CD81 antigen Human genes 0.000 claims abstract description 28
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims abstract description 28
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims abstract description 18
- 102100038081 Signal transducer CD24 Human genes 0.000 claims abstract description 18
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims abstract description 17
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims abstract description 17
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims abstract description 16
- 101000622137 Homo sapiens P-selectin Proteins 0.000 claims abstract description 16
- 101001071312 Homo sapiens Platelet glycoprotein IX Proteins 0.000 claims abstract description 16
- 102100025304 Integrin beta-1 Human genes 0.000 claims abstract description 16
- 102100023472 P-selectin Human genes 0.000 claims abstract description 16
- 102100036851 Platelet glycoprotein IX Human genes 0.000 claims abstract description 16
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims abstract description 15
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims abstract description 15
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims abstract description 14
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims abstract description 14
- 210000004072 lung Anatomy 0.000 claims abstract description 14
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims abstract description 13
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims abstract description 13
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims abstract description 13
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims abstract description 12
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims abstract description 12
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 claims abstract description 11
- 102100032912 CD44 antigen Human genes 0.000 claims abstract description 10
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims abstract description 10
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims abstract description 10
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims abstract description 10
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims abstract description 10
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 claims abstract description 10
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 10
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 claims abstract description 10
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims abstract description 10
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims abstract description 10
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 10
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 claims abstract description 10
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract description 9
- 102100021992 CD209 antigen Human genes 0.000 claims abstract description 9
- 101150013553 CD40 gene Proteins 0.000 claims abstract description 9
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract description 9
- 101000897416 Homo sapiens CD209 antigen Proteins 0.000 claims abstract description 9
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims abstract description 9
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 claims abstract description 9
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims abstract description 9
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims abstract description 9
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 claims abstract description 9
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims abstract description 9
- 102100032817 Integrin alpha-5 Human genes 0.000 claims abstract description 9
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims abstract description 9
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims abstract description 9
- 102100030859 Tissue factor Human genes 0.000 claims abstract description 9
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract description 8
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims abstract description 8
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims abstract description 8
- 230000032683 aging Effects 0.000 claims abstract description 8
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims abstract description 7
- 210000003734 kidney Anatomy 0.000 claims abstract description 7
- 210000000952 spleen Anatomy 0.000 claims abstract description 7
- 230000009885 systemic effect Effects 0.000 claims abstract description 7
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 137
- 210000002826 placenta Anatomy 0.000 claims description 134
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 230000001154 acute effect Effects 0.000 claims description 36
- 102000004127 Cytokines Human genes 0.000 claims description 31
- 108090000695 Cytokines Proteins 0.000 claims description 31
- 230000003169 placental effect Effects 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 210000004700 fetal blood Anatomy 0.000 claims description 19
- 210000001519 tissue Anatomy 0.000 claims description 19
- 108700011259 MicroRNAs Proteins 0.000 claims description 17
- 239000003550 marker Substances 0.000 claims description 17
- 210000000056 organ Anatomy 0.000 claims description 17
- 208000006011 Stroke Diseases 0.000 claims description 15
- 208000030090 Acute Disease Diseases 0.000 claims description 14
- 208000017667 Chronic Disease Diseases 0.000 claims description 14
- 230000033115 angiogenesis Effects 0.000 claims description 14
- 208000014674 injury Diseases 0.000 claims description 14
- 230000006378 damage Effects 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 10
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 10
- 238000011084 recovery Methods 0.000 claims description 10
- 208000028867 ischemia Diseases 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 208000010285 Ventilator-Induced Lung Injury Diseases 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 208000023589 ischemic disease Diseases 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 208000019229 Spleen disease Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 208000030533 eye disease Diseases 0.000 claims description 6
- 108091027963 non-coding RNA Proteins 0.000 claims description 6
- 102000042567 non-coding RNA Human genes 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 208000027140 splenic disease Diseases 0.000 claims description 6
- 230000000451 tissue damage Effects 0.000 claims description 6
- 231100000827 tissue damage Toxicity 0.000 claims description 6
- 208000025721 COVID-19 Diseases 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000014644 Brain disease Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 108091068853 Homo sapiens miR-100 stem-loop Proteins 0.000 claims description 4
- 108091067618 Homo sapiens miR-181a-2 stem-loop Proteins 0.000 claims description 4
- 108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 claims description 4
- 108091070494 Homo sapiens miR-22 stem-loop Proteins 0.000 claims description 4
- 108091065428 Homo sapiens miR-26a-2 stem-loop Proteins 0.000 claims description 4
- 108091070399 Homo sapiens miR-26b stem-loop Proteins 0.000 claims description 4
- 108091067650 Homo sapiens miR-30d stem-loop Proteins 0.000 claims description 4
- 108091065457 Homo sapiens miR-99b stem-loop Proteins 0.000 claims description 4
- 206010067125 Liver injury Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 108091008065 MIR21 Proteins 0.000 claims description 4
- 208000029033 Spinal Cord disease Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 208000015322 bone marrow disease Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000008960 Diabetic foot Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 108010057085 cytokine receptors Proteins 0.000 claims description 3
- 102000003675 cytokine receptors Human genes 0.000 claims description 3
- 201000002818 limb ischemia Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 102100037685 60S ribosomal protein L22 Human genes 0.000 claims description 2
- 101710187788 60S ribosomal protein L22 Proteins 0.000 claims description 2
- 102100020969 ATP-binding cassette sub-family E member 1 Human genes 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 206010048946 Anal abscess Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 102100021745 BRO1 domain-containing protein BROX Human genes 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 102100022533 Calcium-binding protein 39 Human genes 0.000 claims description 2
- 101710148947 Calcium-binding protein 39 Proteins 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 208000021479 Cardiovascular injury Diseases 0.000 claims description 2
- 101710144787 Cell surface glycoprotein MUC18 Proteins 0.000 claims description 2
- 208000009043 Chemical Burns Diseases 0.000 claims description 2
- 208000018380 Chemical injury Diseases 0.000 claims description 2
- 108050001642 Chloride intracellular channel protein 5 Proteins 0.000 claims description 2
- 102000011338 Chloride intracellular channel protein 5 Human genes 0.000 claims description 2
- 206010008635 Cholestasis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009895 Colitis ischaemic Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 102100025525 Cullin-5 Human genes 0.000 claims description 2
- 101710094483 Cullin-5 Proteins 0.000 claims description 2
- 208000026292 Cystic Kidney disease Diseases 0.000 claims description 2
- 102100039868 Cytoplasmic aconitate hydratase Human genes 0.000 claims description 2
- 101710194502 Cytoplasmic aconitate hydratase Proteins 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 208000019800 Early-onset non-syndromic cataract Diseases 0.000 claims description 2
- 208000020564 Eye injury Diseases 0.000 claims description 2
- 206010061172 Gastrointestinal injury Diseases 0.000 claims description 2
- 102100021223 Glucosidase 2 subunit beta Human genes 0.000 claims description 2
- 108050000822 Glucosidase 2 subunit beta Proteins 0.000 claims description 2
- 206010056559 Graft infection Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 101710171815 Guanine nucleotide-binding protein G(s) subunit alpha Proteins 0.000 claims description 2
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 claims description 2
- 101000783786 Homo sapiens ATP-binding cassette sub-family E member 1 Proteins 0.000 claims description 2
- 101000896790 Homo sapiens BRO1 domain-containing protein BROX Proteins 0.000 claims description 2
- 108091067469 Homo sapiens miR-181a-1 stem-loop Proteins 0.000 claims description 2
- 108091070372 Homo sapiens miR-26a-1 stem-loop Proteins 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 206010022680 Intestinal ischaemia Diseases 0.000 claims description 2
- 208000000913 Kidney Calculi Diseases 0.000 claims description 2
- 206010023424 Kidney infection Diseases 0.000 claims description 2
- 102100022892 Kynurenine-oxoglutarate transaminase 3 Human genes 0.000 claims description 2
- 101710165098 Kynurenine-oxoglutarate transaminase 3 Proteins 0.000 claims description 2
- 102100027450 Laminin subunit alpha-5 Human genes 0.000 claims description 2
- 101710200521 Laminin subunit alpha-5 Proteins 0.000 claims description 2
- 108091007773 MIR100 Proteins 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000004535 Mesenteric Ischemia Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 208000003926 Myelitis Diseases 0.000 claims description 2
- 206010028570 Myelopathy Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 102100037594 Programmed cell death protein 10 Human genes 0.000 claims description 2
- 101710187936 Programmed cell death protein 10 Proteins 0.000 claims description 2
- 101710094499 Proteasome subunit beta type-4 Proteins 0.000 claims description 2
- 102100035763 Proteasome subunit beta type-7 Human genes 0.000 claims description 2
- 101710094473 Proteasome subunit beta type-7 Proteins 0.000 claims description 2
- 101710084434 Protein arginine N-methyltransferase 1 Proteins 0.000 claims description 2
- 102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 206010061481 Renal injury Diseases 0.000 claims description 2
- 102100027979 Semaphorin-3B Human genes 0.000 claims description 2
- 101710199438 Semaphorin-3B Proteins 0.000 claims description 2
- 208000028990 Skin injury Diseases 0.000 claims description 2
- 102100024690 Spliceosome RNA helicase DDX39B Human genes 0.000 claims description 2
- 101710086340 Spliceosome RNA helicase DDX39B Proteins 0.000 claims description 2
- 101710096024 Syntaxin-binding protein 3 Proteins 0.000 claims description 2
- 102100021679 Syntaxin-binding protein 3 Human genes 0.000 claims description 2
- 102100035715 Transcriptional activator protein Pur-alpha Human genes 0.000 claims description 2
- 101710196852 Transcriptional activator protein Pur-alpha Proteins 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 231100000439 acute liver injury Toxicity 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims description 2
- 230000007000 age related cognitive decline Effects 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 210000003780 hair follicle Anatomy 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 231100000234 hepatic damage Toxicity 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000037906 ischaemic injury Diseases 0.000 claims description 2
- 201000008222 ischemic colitis Diseases 0.000 claims description 2
- 230000003907 kidney function Effects 0.000 claims description 2
- 208000037806 kidney injury Diseases 0.000 claims description 2
- 201000002364 leukopenia Diseases 0.000 claims description 2
- 231100001022 leukopenia Toxicity 0.000 claims description 2
- 230000008818 liver damage Effects 0.000 claims description 2
- 208000018191 liver inflammation Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000001151 other effect Effects 0.000 claims description 2
- 210000004991 placental stem cell Anatomy 0.000 claims description 2
- 239000002574 poison Substances 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 208000014081 polyp of colon Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 230000037380 skin damage Effects 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 239000003104 tissue culture media Substances 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 4
- 102100022297 Integrin alpha-X Human genes 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000002953 phosphate buffered saline Substances 0.000 description 47
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 45
- 230000035755 proliferation Effects 0.000 description 34
- 239000008194 pharmaceutical composition Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 239000002609 medium Substances 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 239000006228 supernatant Substances 0.000 description 23
- 238000002955 isolation Methods 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 210000002919 epithelial cell Anatomy 0.000 description 18
- 239000008188 pellet Substances 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 238000005119 centrifugation Methods 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 208000004852 Lung Injury Diseases 0.000 description 9
- 206010069363 Traumatic lung injury Diseases 0.000 description 9
- 238000001042 affinity chromatography Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000002738 chelating agent Substances 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 102000000412 Annexin Human genes 0.000 description 8
- 108050008874 Annexin Proteins 0.000 description 8
- 102100027217 CD82 antigen Human genes 0.000 description 8
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 8
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 8
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 8
- 101000836492 Dictyostelium discoideum ALG-2 interacting protein X Proteins 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 8
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 8
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 8
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 8
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 8
- 101001134621 Homo sapiens Programmed cell death 6-interacting protein Proteins 0.000 description 8
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 8
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 102000042022 Rab family Human genes 0.000 description 8
- 108091079902 Rab family Proteins 0.000 description 8
- 108060000864 flotillin Proteins 0.000 description 8
- 102000010660 flotillin Human genes 0.000 description 8
- 231100000515 lung injury Toxicity 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000002679 microRNA Substances 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000001398 Granzyme Human genes 0.000 description 7
- 108060005986 Granzyme Proteins 0.000 description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 229930192851 perforin Natural products 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 6
- 210000005059 placental tissue Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 5
- 108010077805 Bacterial Proteins Proteins 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 5
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 4
- 102100032412 Basigin Human genes 0.000 description 4
- 102100032449 EGF-like repeat and discoidin I-like domain-containing protein 3 Human genes 0.000 description 4
- 102100037362 Fibronectin Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000010956 Glypican Human genes 0.000 description 4
- 108050001154 Glypican Proteins 0.000 description 4
- 108050007238 Glypican-1 Proteins 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 4
- 101001016381 Homo sapiens EGF-like repeat and discoidin I-like domain-containing protein 3 Proteins 0.000 description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 4
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 4
- 102100023123 Mucin-16 Human genes 0.000 description 4
- 108010002687 Survivin Proteins 0.000 description 4
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229960001484 edetic acid Drugs 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003194 forelimb Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 108091070501 miRNA Proteins 0.000 description 4
- 238000012737 microarray-based gene expression Methods 0.000 description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 102000013498 tau Proteins Human genes 0.000 description 4
- 108010026424 tau Proteins Proteins 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LKTNEXPODAWWFM-UHFFFAOYSA-N 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide Chemical compound CC1=CC=CC=C1N=NC(C=C1C)=CC=C1NC(=O)C1=CC=NN1C LKTNEXPODAWWFM-UHFFFAOYSA-N 0.000 description 3
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 3
- 101000951325 Homo sapiens Mitoferrin-1 Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 102100037984 Mitoferrin-1 Human genes 0.000 description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
- 206010034576 Peripheral ischaemia Diseases 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 3
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008568 cell cell communication Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000004252 chorionic villi Anatomy 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000008102 immune modulation Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005399 mechanical ventilation Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000004766 neurogenesis Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000575 proteomic method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000000822 sequential centrifugation Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 2
- MTVVJOBPGQXHML-UHFFFAOYSA-N 6-bromo-N-[(2-hydroxyphenyl)methylideneamino]-2-methylquinoline-4-carboxamide Chemical compound BrC=1C=C2C(=CC(=NC2=CC=1)C)C(=O)NN=CC1=C(C=CC=C1)O MTVVJOBPGQXHML-UHFFFAOYSA-N 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
- 238000000035 BCA protein assay Methods 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 101100278839 Drosophila melanogaster sw gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102000013818 Fractalkine Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 2
- BQYIXOPJPLGCRZ-IDUWFGFVSA-N N-[(Z)-[3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl]methylideneamino]pyridine-4-carboxamide Chemical compound Cc1ncc(CO)c(\C=N/NC(=O)c2ccncc2)c1O BQYIXOPJPLGCRZ-IDUWFGFVSA-N 0.000 description 2
- 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 2
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 2
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 231100000480 WST assay Toxicity 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000009693 chronic damage Effects 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012364 cultivation method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000001985 kidney epithelial cell Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 238000010825 rotarod performance test Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ZWSMLJACYSGFKD-UHFFFAOYSA-J tetrasodium;2-[2-[2-[2-[bis(carboxylatomethyl)amino]phenoxy]ethoxy]-n-(carboxylatomethyl)anilino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC([O-])=O)CC([O-])=O ZWSMLJACYSGFKD-UHFFFAOYSA-J 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100029599 Advanced glycosylation end product-specific receptor Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 description 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001061840 Homo sapiens Advanced glycosylation end product-specific receptor Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 description 1
- 201000005503 Hypoplastic left heart syndrome Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000009913 Peroxisomal Targeting Signal 2 Receptor Human genes 0.000 description 1
- 108010077056 Peroxisomal Targeting Signal 2 Receptor Proteins 0.000 description 1
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 101100465559 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRE7 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- GNJXVFXIDHCCKR-UHFFFAOYSA-N acetyloxymethyl 2-[[2-(acetyloxymethoxy)-2-oxoethyl]-[2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]ethoxy]ethoxy]ethyl]amino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)CCOCCOCCN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O GNJXVFXIDHCCKR-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000011797 cavity material Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 101150062988 dapF gene Proteins 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000009443 proangiogenesis Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 101150076896 pts1 gene Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- GUGNSJAORJLKGP-UHFFFAOYSA-K sodium 8-methoxypyrene-1,3,6-trisulfonate Chemical compound [Na+].[Na+].[Na+].C1=C2C(OC)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 GUGNSJAORJLKGP-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863767P | 2019-06-19 | 2019-06-19 | |
| US62/863,767 | 2019-06-19 | ||
| US201962891700P | 2019-08-26 | 2019-08-26 | |
| US62/891,700 | 2019-08-26 | ||
| US201962905117P | 2019-09-24 | 2019-09-24 | |
| US62/905,117 | 2019-09-24 | ||
| US201962924147P | 2019-10-21 | 2019-10-21 | |
| US62/924,147 | 2019-10-21 | ||
| PCT/US2020/038828 WO2020257720A1 (en) | 2019-06-19 | 2020-06-19 | Exosomes for disease treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020298316A1 true AU2020298316A1 (en) | 2021-12-16 |
Family
ID=71662298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020298316A Abandoned AU2020298316A1 (en) | 2019-06-19 | 2020-06-19 | Exosomes for disease treatment |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230181649A1 (enExample) |
| EP (1) | EP3986381A1 (enExample) |
| JP (1) | JP2022538004A (enExample) |
| KR (1) | KR20220024060A (enExample) |
| CN (1) | CN114302731A (enExample) |
| AU (1) | AU2020298316A1 (enExample) |
| BR (1) | BR112021025512A2 (enExample) |
| CA (1) | CA3142020A1 (enExample) |
| IL (1) | IL288958A (enExample) |
| MX (1) | MX2021015528A (enExample) |
| PH (1) | PH12021553167A1 (enExample) |
| WO (1) | WO2020257720A1 (enExample) |
| ZA (1) | ZA202109828B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3801028A4 (en) | 2018-05-30 | 2022-04-13 | Direct Biologics LLC | A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use |
| IL320107A (en) | 2019-02-07 | 2025-06-01 | Direct Biologics Llc | Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds |
| WO2021011935A1 (en) | 2019-07-18 | 2021-01-21 | Direct Biologics, Llc | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
| US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
| US20210324339A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
| MX2022013301A (es) | 2020-04-22 | 2023-02-14 | Direct Biologics Llc | Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa. |
| KR102317052B1 (ko) * | 2020-05-04 | 2021-10-25 | 주식회사 티에스셀바이오 | 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물 |
| WO2022154149A1 (ko) * | 2021-01-14 | 2022-07-21 | (주)엑솔런스 | 세포외소포체를 이용한 백신 조성물 |
| US20240307438A1 (en) * | 2021-02-26 | 2024-09-19 | The Methodist Hospital | Regulatory T Cell (Treg) Extracellular Vesicle Compositions and Methods |
| CN113171379A (zh) * | 2021-04-28 | 2021-07-27 | 奥启(深圳)创投科技有限公司 | 一种间充质干细胞外泌体在制备脂肪性肝病药物中的应用 |
| CN114085817B (zh) * | 2021-11-26 | 2025-04-15 | 三代康年(上海)医疗科技有限公司 | 一种包载microRNA的外泌体的制备方法及其产品和应用 |
| EP4507718A4 (en) * | 2022-04-08 | 2026-07-29 | Innovative Surgical Regeneration Holdings Llc | NAMPT FOR HEALING AND STIMULATING HAIR GROWTH AND/OR REGROWTH |
| CN117414415B (zh) * | 2023-07-10 | 2024-10-18 | 中山大学·深圳 | 蛋白质精氨酸甲基转移酶7在促进毛发生长中的应用 |
| KR20250033996A (ko) * | 2023-08-31 | 2025-03-10 | 의료법인 성광의료재단 | 인간 태반 유래 중간엽 줄기 세포에서 분리된 엑소좀을 포함하는 시신경 질환 및 미토콘드리아 기능이상 질환 예방 또는 치료용 약학적 조성물 |
| KR20250139693A (ko) * | 2024-03-15 | 2025-09-23 | 가톨릭대학교 산학협력단 | Ssea3 및 cd105를 발현하는 신경능 유래 코 줄기세포 유효성분으로 포함하는 알츠하이머병 예방 또는 치료용 약학적 조성물 |
| WO2025226276A1 (en) | 2024-04-25 | 2025-10-30 | Direct Biologics, Llc | Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles |
| CN120437174B (zh) * | 2025-02-28 | 2026-06-16 | 单核细胞治疗有限公司 | 脐带血外泌体在制备治疗衰老引发的眼科疾病的药物中的应用 |
| CN120927522B (zh) * | 2025-10-14 | 2026-02-03 | 亿航(苏州)生物医药有限公司 | 辅助诊断或鉴别血管性认知障碍的标志物、试剂盒及用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2484782B1 (en) * | 2006-01-05 | 2015-11-18 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
| CA2705486C (en) * | 2007-11-19 | 2019-04-02 | Celera Corporation | Lung cancer markers and uses thereof |
| AR075239A1 (es) * | 2009-02-04 | 2011-03-16 | Bipar Sciences Inc | Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso |
| AU2015330855A1 (en) * | 2014-10-09 | 2017-04-27 | Celularity Inc. | Placenta-derived adherent cell exosomes and uses thereof |
| NZ737556A (en) * | 2015-05-26 | 2022-11-25 | Celularity Inc | Angiogenesis using stimulated placental stem cells |
| CN105861430B (zh) * | 2016-04-29 | 2019-07-23 | 南京大学 | 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用 |
| AU2017354272A1 (en) * | 2016-11-03 | 2019-05-23 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
| CN119552810A (zh) * | 2017-11-16 | 2025-03-04 | 细胞结构公司 | 用以分离外泌体的胎盘培养 |
-
2020
- 2020-06-19 CN CN202080042501.XA patent/CN114302731A/zh active Pending
- 2020-06-19 US US17/596,827 patent/US20230181649A1/en active Pending
- 2020-06-19 PH PH1/2021/553167A patent/PH12021553167A1/en unknown
- 2020-06-19 CA CA3142020A patent/CA3142020A1/en active Pending
- 2020-06-19 JP JP2021575247A patent/JP2022538004A/ja active Pending
- 2020-06-19 KR KR1020217041154A patent/KR20220024060A/ko not_active Ceased
- 2020-06-19 MX MX2021015528A patent/MX2021015528A/es unknown
- 2020-06-19 BR BR112021025512A patent/BR112021025512A2/pt not_active IP Right Cessation
- 2020-06-19 WO PCT/US2020/038828 patent/WO2020257720A1/en not_active Ceased
- 2020-06-19 AU AU2020298316A patent/AU2020298316A1/en not_active Abandoned
- 2020-06-19 EP EP20742527.3A patent/EP3986381A1/en not_active Withdrawn
-
2021
- 2021-12-01 ZA ZA2021/09828A patent/ZA202109828B/en unknown
- 2021-12-13 IL IL288958A patent/IL288958A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114302731A (zh) | 2022-04-08 |
| BR112021025512A2 (pt) | 2022-02-01 |
| ZA202109828B (en) | 2024-04-24 |
| MX2021015528A (es) | 2022-02-03 |
| KR20220024060A (ko) | 2022-03-03 |
| CA3142020A1 (en) | 2020-12-24 |
| PH12021553167A1 (en) | 2022-08-15 |
| WO2020257720A1 (en) | 2020-12-24 |
| EP3986381A1 (en) | 2022-04-27 |
| IL288958A (en) | 2022-02-01 |
| US20230181649A1 (en) | 2023-06-15 |
| JP2022538004A (ja) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3986381A1 (en) | Exosomes for disease treatment | |
| JP2024023185A (ja) | エキソソームを単離するための胎盤の培養 | |
| US20250257323A1 (en) | Activation-induced tissue-effector cells suitable for cell therapy and extracelluar vesicles derived therefrom | |
| US9877989B2 (en) | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions | |
| EP3226875B1 (en) | Processes for producing stable exosome formulations | |
| EP3029061B1 (en) | Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage | |
| CA2646384C (en) | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | |
| US20230330154A1 (en) | Methods of treating systemic graft- versus-host disease with extracellular vesicles | |
| KR102213527B1 (ko) | 패혈증 치료용 중간엽 기질세포 | |
| US20230143893A1 (en) | Isolation and purification of exosomes for regenerative medicine | |
| CA2871219C (en) | Immune privileged and modulatory progenitor cells | |
| CN113973498A (zh) | 源自间充质干细胞的外泌体生产方法及利用其制备的培养液 | |
| CA3216129A1 (en) | Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells | |
| JP6722598B2 (ja) | 関節リウマチ治療のための間葉系間質細胞 | |
| CN110536689A (zh) | 扩张型心肌病治疗剂 | |
| US20150190431A1 (en) | Method for isolating stem cells and their use in cell therapy | |
| KR20250034958A (ko) | 저온보존된 중간체 및 그에 대한 효력 검정 | |
| US20230365937A1 (en) | Mesenchymal stem cells and their culture | |
| WO2026096838A1 (en) | Treatment of organ dysfunction using a combination of mesenchymal stem cells and exosomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |